Company intelligence / Profile preview
SCYNEXIS, Inc.
Jersey City, New Jersey, United Statesscynexis.com ↗
- Ownership
- Public · SCYX
- Employees
- ~40
- Development stage
- Other
01
Overview
BREXAFEMME® (ibrexafungerp) was FDA approved in June 2021 for VVC and in November 2022 for RVVC. Late-stage clinical trials are ongoing in invasive fungal infections. Next-generation compound SCY‑247 has entered Phase 1 trials as of early 2025.[5][7][9]
- Therapeutic areas
- Women's HealthInfectious Diseases
- Modalities
- Small molecules (notably triterpenoid antifungals called "fungerps")[3][6]
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
GSK – exclusive license agreement to commercialize and further develop Brexafemme/ibrexafungerp for VVC/RVVC/invasive candidiasis [8]
04
Financials
- Market cap
- $20.8M
- Total revenue
- $20.6M
- Enterprise value
- $-24.6M
Beyond the preview
Go deeper on SCYNEXIS, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCYNEXIS, Inc..